Provided by Tiger Fintech (Singapore) Pte. Ltd.

Collegium Pharmaceutical

26.79
+0.01000.04%
Post-market: 26.790.00000.00%16:20 EDT
Volume:214.44K
Turnover:5.72M
Market Cap:860.81M
PE:14.43
High:27.09
Open:26.60
Low:26.22
Close:26.78
Loading ...

Collegium Appoints Nancy S. Lurker to Its Board of Directors

THOMSON REUTERS
·
05 Feb

Press Release: Collegium Appoints Nancy S. Lurker to its Board of Directors

Dow Jones
·
05 Feb

Collegium Pharmaceutical price target lowered to $36 from $37 at Piper Sandler

TIPRANKS
·
04 Feb

Piper Sandler Keeps Their Hold Rating on Collegium Pharmaceutical (COLL)

TIPRANKS
·
04 Feb

Despite the downward trend in earnings at Collegium Pharmaceutical (NASDAQ:COLL) the stock swells 18%, bringing three-year gains to 82%

Simply Wall St.
·
14 Jan

Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46

MT Newswires Live
·
10 Jan

Collegium Pharmaceutical upgraded to Buy from Hold at Needham

TIPRANKS
·
10 Jan

Collegium Pharmaceutical Raised to Buy From Hold by Needham

Dow Jones
·
10 Jan

Collegium Pharmaceutical Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

Collegium Pharmaceutical Shares Rise After 2025 Guidance

MT Newswires Live
·
09 Jan

BRIEF-Collegium Provides 2025 Financial Guidance And Business Update

Reuters
·
08 Jan

Collegium Pharmaceutical Unveils 2025 Financial Projections

TIPRANKS
·
08 Jan

BRIEF-Collegium Pharmaceutical Outlook FY Revenue USD 735-750 Million

Reuters
·
08 Jan

Collegium Pharmaceutical Inc - 2025 Product Revenues Expected in Range of $735 Mln to $750 Mln

THOMSON REUTERS
·
08 Jan

Collegium Provides 2025 Financial Guidance and Business Update

THOMSON REUTERS
·
08 Jan

Collegium Pharmaceutical Outlook FY Revenue USD 735-750 Million

THOMSON REUTERS
·
08 Jan

Press Release: Collegium Provides 2025 Financial Guidance and Business Update

Dow Jones
·
08 Jan

Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus

Simply Wall St.
·
25 Dec 2024

Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet

Simply Wall St.
·
24 Dec 2024

Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.
·
14 Nov 2024